Drug profile · INN
elagolix sodium
ORILISSA
elagolix sodium (ORILISSA) is a gonadotropin-releasing hormone receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — elagolix sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 4
- Programs
- 0
- Data quality
- 0.84
Quick answer
elagolix sodium (ORILISSA) is a gonadotropin-releasing hormone receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Gonadotropin-releasing hormone receptor antagonist
Primary target: Gonadotropin-releasing hormone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
-
US 12102637
Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
granted -
US 12083227
Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
granted -
US 11459305
Processes for the preparation of uracil derivatives
granted -
US 7419983
Gonadotropin-releasing hormone receptor antagonists and methods related thereto
granted
Frequently asked questions
What is elagolix sodium?
elagolix sodium (ORILISSA) is a gonadotropin-releasing hormone receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for elagolix sodium?
ORILISSA is a marketed brand name for elagolix sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of elagolix sodium?
elagolix sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.